Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) Interest & Investment Income: 2016-2025

Historic Interest & Investment Income for Rocket Pharmaceuticals (RCKT) over the last 9 years, with Sep 2025 value amounting to $709,000.

  • Rocket Pharmaceuticals' Interest & Investment Income fell 46.57% to $709,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 million, marking a year-over-year decrease of 44.47%. This contributed to the annual value of $8.3 million for FY2024, which is 56.34% up from last year.
  • As of Q3 2025, Rocket Pharmaceuticals' Interest & Investment Income stood at $709,000, which was up 46.79% from $483,000 recorded in Q2 2025.
  • In the past 5 years, Rocket Pharmaceuticals' Interest & Investment Income registered a high of $3.0 million during Q1 2024, and its lowest value of $483,000 during Q2 2025.
  • Moreover, its 3-year median value for Interest & Investment Income was $1.3 million (2025), whereas its average is $1.5 million.
  • Its Interest & Investment Income has fluctuated over the past 5 years, first surged by 258.65% in 2021, then slumped by 78.95% in 2025.
  • Rocket Pharmaceuticals' Interest & Investment Income (Quarterly) stood at $850,000 in 2021, then spiked by 46.47% to $1.2 million in 2022, then tumbled by 34.62% to $814,000 in 2023, then surged by 98.65% to $1.6 million in 2024, then crashed by 46.57% to $709,000 in 2025.
  • Its Interest & Investment Income stands at $709,000 for Q3 2025, versus $483,000 for Q2 2025 and $1.3 million for Q1 2025.